Laidlaw Capital Markets

The Laidlaw Capital Markets team has extensive experience in executing transactions of both debt and equity of all categories in both the private and public markets.

We strive to build long term relationships with exciting and growth-oriented companies with a focus in the Healthcare and technology verticals. While leveraging our diverse institutional and retail network of quality investors, we are able to deliver quality results for our clients through a variety of products. Our team is able to help organizations strategize and navigate goals on an individual company basis to help them achieve their desired results.

  • Initial Public Offering (IPO)
  • Follow-On Offering
  • Confidentially Marketed Public Offering (CMPO)
  • Registered Direct (RD)
  • PIPE Transaction
  • Private Placement
  • Block trade

Investment Banking Team

James P. Ahern
James P. AhernManaging Partner, Head of Capital Markets

Jim joined the firm in October of 2010, and focuses on arranging financings for both private and public companies, mainly within the healthcare vertical. Over Jim’s Laidlaw tenure, he has led or played an integral role in capital raises totaling $3 billion of transaction value. Moreover, he has strategically grown Laidlaw’s Capital Markets’ team, and overseen the firm’s significant market share expansion.
Outside of the firm, Mr. Ahern is on the Board of Overseers for the Massachusetts Bay Big Brothers Big Sisters Foundation. Jim is also Vice-Chair of the BBBS Annual Golf Outing, an event which raises nearly 1 million dollars annually for the foundation. An active supporter of his Alma Mater, The Northfield Mount Hermon School, Jim serves as President of the NMH Basketball Alumni Council for Excellence.
Luke Kottke
Luke KottkeSenior Managing Director

Luke Kottke serves as Senior Managing Director within the Global Capital Markets group where he joined in 2011. Mr. Kottke also serves as Head of Syndicate. Prior to joining Laidlaw, Mr. Kottke served as Vice President on the Global Capital Markets desk at a publicly traded investment banking firm in New York City. Over his career, he has been instrumental in raising over $3 billion of capital in several hundred investment banking transactions, with a focus on the Healthcare and Technology sectors, leveraging his strong relationships with buy-side investment firms across Wall Street. Mr. Kottke’s expertise in selling investment banking products and research has made him an invaluable resource to numerous banking clients. He began his career at Sonostar Capital Partners, a venture capital and private equity firm. Mr. Kottke also worked at Merrill Lynch as a financial advisor where he earned his series 7 and 66 licenses. Outside of the firm, Luke is a member of the Big Brothers Big Sister of MA’s Annual Charity Golf Event and is also involved in the Pyro’s Wings Foundation. Luke is a graduate of the University of Scranton and resides in New Jersey with his wife and three children.
Mathew Moschovas
Mathew MoschovasSenior Associate, Global Capital Markets

Mathew Moschovas is a Senior Associate on the Global Capital Markets Desk where he joined in 2017. Matt has helped in providing capital-raising solutions for micro-cap to mid-cap companies across multiple sectors via IPO, Secondary, PIPE, Private Placement, Bridge Loan, Reverse Merger, and Registered Direct offerings. He has assisted in raises for both public and private companies during his time, totaling over $1 billion. He also assists on the Syndicate Desk, gaining access to bulge bracket firm led IPO’s and Secondaries. Matt is a graduate of Montclair State University with a BA in Finance. Matt is a former collegiate baseball player and 4-year starter. Outside of the firm, Matt is a member of the B+ Foundation, an organization devoted to financial assistance, cancer research, and awareness, for children.

Investment Banking Advisory

Laidlaw is committed to partnering with organizations in an advisory capacity. Our team of bankers’ focus on the healthcare industry and the depth of their experience allows them to provide comprehensive knowledge of both the industry and the markets. Our team is able to help organizations strategize and navigate goals on an individual company basis. Whether one is seeking transactions such as acquisitions, divestitures, and mergers, or “going private” transactions and management-led buyouts, we have the resources, experience, and capabilities to work closely with clients to achieve the desired results.

All of our offerings

2019-11-15T19:03:49+00:00


Affimed

Follow On Offering
Common Stock
.

$34,500,000

Co-Manager
November 2019

2018-05-14T13:55:01+00:00

MEI
Pharma

PIPE Transaction
Common Stock and Warrants
 

$75,000,000

Co-Placement Agent
May 2018

2018-05-17T20:34:24+00:00

Sesen
Bio

Registered Direct
Common Stock and
Warrants

$10,000,000

Exclusive Placement Agent
March 2018

2018-06-01T01:40:10+00:00


AIT Therapeutics

PIPE Transaction
Warrants
.

$9,820,154.54

Exclusive Placement Agent
February 2018

2018-05-04T14:37:33+00:00


Affimed

Follow-On Offering
Common Stock
 

$23,000,000

Financial Advisor
February 2018

2018-05-04T14:41:44+00:00

Cytori
Therapeutics

Rights Offering
Convertible Preferred
Stock and Warrants

$10,000,000

Financial Advisor
November 2017

2018-05-04T15:09:37+00:00

Onconova
Therapeutics

Registered Direct
Common Stock
 

$1,380,000

Sole Placement Agent
November 2017

2018-05-04T15:20:13+00:00

Repros
Therapeutics

Confidentially Marketed
Public Offering
Common Stock and Warrants

$3,000,000

Sole Book-Runner
May 2017

2018-05-04T15:27:52+00:00

Onconova
Therapeutics

Confidentially Marketed
Public Offering
Common Stock

$5,963,517

Sole Book Runner
April 2017

2018-05-04T15:34:41+00:00


BioSig Technologies

PIPE Transaction
Common Stocks
& Warrants

$4,349,954

Exclusive Placement Agent
March 2017

2018-05-04T15:28:33+00:00

Therapix
Biosciences

Initial Public Offering
Common Stock
 

$13,800,000

Sole Book Runner
March 2017

2018-05-04T15:28:47+00:00

Gemphire

PIPE Transaction
Common Stock & Warrants
 

$12,500,000

Co-Manager
March 2017

2018-05-04T15:32:10+00:00


AIT Therapeutics

PIPE Transaction,
Common Stock
and Warrants

$10,200,000

Placement Agent
March 2017

2018-05-04T15:32:33+00:00


Evoke Pharma

Confidentially Marketed
Follow-On
Common Stock

$8,050,000

Sole Book Runner
February 2017

2018-05-04T15:34:50+00:00


Medovex Corporation

PIPE Transaction
Common Stock & Warrants
 

$3,022,000

Exclusive Placement Agent
February 2017

2018-05-04T15:57:47+00:00

Medovex
Corporation

PIPE Transaction
Common Stock
& Warrants

$1,398,033

Placement Agent
April 2016

2018-05-04T15:48:50+00:00


ImmunoCellular

Follow-On Offering
Common Stocks
& Warrants

$7,400,000

Lead Manager
August 2016

2018-05-04T15:45:14+00:00


Gemphire

Initial Public Offering
Common Stock
 

$30,000,000

Co-Manager
August 2016

2018-05-04T15:46:19+00:00


PhaseRx

Initial Public Offering
Common Stock
 

$18,500,000

Book Runner
May 2016

2018-05-04T15:55:48+00:00

Aeolus
Pharmaceuticals

PIPE Transaction
Common Stock
& Warrants

$6,750,000

Exclusive Placement Agent
December 2015

2018-05-04T15:54:44+00:00


Cerecor, Inc.

Initial Public Offering
Common Stock
& Warrants

$26,000,000

Lead Manager
October 2015

2018-05-04T15:59:54+00:00

Sevion
Therapeutics

PIPE Transaction
Common Stocks
& Warrants

$7,325,217

Exclusive Placement Agent
July 2015

2018-05-04T16:00:52+00:00

Viking
Therapeutics

Initial Public Offering
Common Stock
 

$27,600,000

Sole Book-Runner
May 2015

2018-05-04T16:03:10+00:00


ADMA Biologics

Follow-On Offering
Common Stock
 

$9,800,000

Co-Manager
March 2015

2018-05-04T16:03:50+00:00

Medovex
Corporation

Initial Public Offering
Common Stock
& Warrants

$9,200,000

Sole Book-Runner
December 2014

2018-05-04T16:04:24+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$7,000,000

Sole Book-Runner
October 2014

2018-05-04T16:05:10+00:00

Relmada
Therapeutics

 
Common Stock & Warrants
 

$28,000,000

Exclusive Placement Agent
June 2014

2018-05-04T16:05:31+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$10,000,000

Joint Book-Runner
April 2014

2018-05-04T16:11:19+00:00

Cel-Sci
Corporation

Follow-On offering
Common Stock & Warrants
 

$3,000,000

Sole Book-runner
December 2013

2018-05-04T16:11:34+00:00


ADMA Biologics

Initial Public Offering
Common Stock
 

$28,347,500

Co-Manager
October 2013

2018-05-04T16:11:55+00:00

Cel-Sci
Corporation

Follow-On Offering
Common Stock
& Warrants

$17,826,087

Co-Manager
October 2013

2018-05-04T16:12:06+00:00

Relmada
Therapeutics

Convertible
Preferred Stock
& Warrants

$8,000,000

Placement Agent
September 2013

2018-05-04T16:12:39+00:00

Relmada
Therapeutics

Convertible Bridge
Notes & Warrants
 

$750,000

Placement Agent
September 2013

2018-05-04T16:12:58+00:00


Alliqua

Common Stock &
Warrants
 

$3,000,000

Co-Manager
July 2013

2018-05-04T16:13:03+00:00

BioSig
Technologies

Convertible
Preferred Stock
 

$2,800,000

Exclusive Placement Agent
July 2013